| scholarly article | Q13442814 |
| P50 | author | Gérard Socié | Q19859709 |
| Jean-David Bouaziz | Q55241522 | ||
| P2093 | author name string | Armand Bensussan | |
| Jean-David Bouaziz | |||
| Martine Bagot | |||
| Adèle de Masson | |||
| P2860 | cites work | B cells in chronic graft-versus-host disease | Q26861706 |
| Current issues in chronic graft-versus-host disease | Q33917187 | ||
| CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients | Q34093165 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD | Q34292984 | ||
| IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases | Q34658996 | ||
| A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses | Q34778834 | ||
| CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. | Q50757178 | ||
| IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro | Q51038853 | ||
| P433 | issue | 7 | |
| P304 | page(s) | e1016707 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Deficient regulatory B cells in human chronic graft-versus-host disease | |
| P478 | volume | 4 |
| Q47402442 | Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease |
| Q26738867 | B cell regulation of the anti-tumor response and role in carcinogenesis |
| Q37587724 | B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation |
| Q38668025 | New answers to old conundrums: what antibodies, exosomes and inflammasomes bring to the conversation. Canadian National Transplant Research Program international summit report |
| Q90340384 | Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes |
Search more.